ARWR (Arrowhead Pharmaceuticals, Inc.) צמיחת רווחי EPS רבעונית
The quarterly EPS growth snapshot demonstrates profitability dynamics, where -1628.20 expresses the current value of the metric for Arrowhead Pharmaceuticals (ARWR). The delivery of RNA drugs requires costly temperature control to preserve their properties. Meanwhile, the TRiM platform provides significant pricing power due to its unique impact on genes. Arrowhead Pharmaceuticals (ARWR) is currently preparing to scale, although massive R&D expenditures are keeping net income low.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_ARWR_-_Arrowhead-Pharmaceuticals_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "arrowheadpharma.com (ARWR): צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים מ-04.07.2022 עד 15.11.2026 | 👁️GURU.Markets👁️")
arrowheadpharma.com (ARWR) - פילוחי מדדים ודוחות פיננסיים
Quarterly EPS growth measures the percentage change in net income per share, reflecting the efficiency of business capitalization. Professionals utilize this rate to assess profit scalability and market consensus. By analyzing the quarterly EPS chart, an investor can see the current value of -1628.20. This indicator is critical for Arrowhead Pharmaceuticals (ARWR), as its growth will be driven by the successful market launch of RNAi drugs for respiratory and liver therapies.
